Genome-based approaches to develop vaccines against bacterial pathogens.
Bacterial infectious diseases remain the single most important threat to health worldwide. Although conventional vaccinology approaches were successful in conferring protection against several diseases, they failed to provide efficacious solutions against many others. The advent of whole-genome sequencing changed the way to think about vaccine development, enabling the targeting of possible vaccine candidates starting from the genomic information of a single bacterial isolate, with a process named reverse vaccinology. As the genomic era progressed, reverse vaccinology has evolved with a pan-genome approach and multi-strain genome analysis became fundamental for the design of universal vaccines. This review describes the applications of genome-based approaches in the development of new vaccines against bacterial pathogens.
Serruto
Davide
D
Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy.
Serino
Laura
L
Masignani
Vega
V
Pizza
Mariagrazia
M
D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology*; D015195:Drug Design; D010861:Fimbriae, Bacterial / Q000276:immunology; D016680:Genome, Bacterial; D022401:Meningococcal Vaccines / Q000276:immunology; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology; D022242:Pneumococcal Vaccines / Q000276:immunology; D013297:Streptococcus pyogenes / Q000276:immunology
D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines